AU2004228929B2 - Organic compounds - Google Patents

Organic compounds Download PDF

Info

Publication number
AU2004228929B2
AU2004228929B2 AU2004228929A AU2004228929A AU2004228929B2 AU 2004228929 B2 AU2004228929 B2 AU 2004228929B2 AU 2004228929 A AU2004228929 A AU 2004228929A AU 2004228929 A AU2004228929 A AU 2004228929A AU 2004228929 B2 AU2004228929 B2 AU 2004228929B2
Authority
AU
Australia
Prior art keywords
alkyl
composition according
halogen
substituted
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2004228929A
Other languages
English (en)
Other versions
AU2004228929A1 (en
Inventor
Tomoyuki Oomura
Madhusudhan Pudipeddi
Alan Edward Royce
Colleen Ruegger
Masaki Sasaki
Tokuhiro Tamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Mitsubishi Tanabe Pharma Corp
Original Assignee
Novartis AG
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004228929(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG, Mitsubishi Tanabe Pharma Corp filed Critical Novartis AG
Publication of AU2004228929A1 publication Critical patent/AU2004228929A1/en
Priority to AU2008200368A priority Critical patent/AU2008200368B2/en
Application granted granted Critical
Publication of AU2004228929B2 publication Critical patent/AU2004228929B2/en
Assigned to MITSUBISHI TANABE PHARMA CORPORATION, NOVARTIS AG reassignment MITSUBISHI TANABE PHARMA CORPORATION Request to Amend Deed and Register Assignors: MITSUBISHI PHARMA CORPORATION, NOVARTIS AG
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2004228929A 2003-04-08 2004-04-06 Organic compounds Active 2026-02-01 AU2004228929B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008200368A AU2008200368B2 (en) 2003-04-08 2008-01-24 Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08
US60/461,215 2003-04-08
PCT/EP2004/003656 WO2004089341A1 (en) 2003-04-08 2004-04-06 Organic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008200368A Division AU2008200368B2 (en) 2003-04-08 2008-01-24 Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol

Publications (2)

Publication Number Publication Date
AU2004228929A1 AU2004228929A1 (en) 2004-10-21
AU2004228929B2 true AU2004228929B2 (en) 2008-02-07

Family

ID=32326722

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004228929A Active 2026-02-01 AU2004228929B2 (en) 2003-04-08 2004-04-06 Organic compounds

Country Status (41)

Country Link
US (11) US20060275357A1 (cg-RX-API-DMAC7.html)
EP (5) EP2769713A1 (cg-RX-API-DMAC7.html)
JP (3) JP5495467B2 (cg-RX-API-DMAC7.html)
KR (3) KR20110005320A (cg-RX-API-DMAC7.html)
CN (2) CN1767819B (cg-RX-API-DMAC7.html)
AR (3) AR043987A1 (cg-RX-API-DMAC7.html)
AT (3) AT501681B1 (cg-RX-API-DMAC7.html)
AU (1) AU2004228929B2 (cg-RX-API-DMAC7.html)
BE (2) BE1015972A5 (cg-RX-API-DMAC7.html)
BR (1) BRPI0409250B8 (cg-RX-API-DMAC7.html)
CA (2) CA2707750A1 (cg-RX-API-DMAC7.html)
CL (2) CL2004000745A1 (cg-RX-API-DMAC7.html)
CY (3) CY1110260T1 (cg-RX-API-DMAC7.html)
DE (4) DE122011100047I1 (cg-RX-API-DMAC7.html)
DK (2) DK1613288T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP056090A (cg-RX-API-DMAC7.html)
ES (3) ES2228282B1 (cg-RX-API-DMAC7.html)
FR (2) FR2854073B1 (cg-RX-API-DMAC7.html)
GB (1) GB2400318B (cg-RX-API-DMAC7.html)
GR (1) GR1005052B (cg-RX-API-DMAC7.html)
HR (3) HRP20050886B1 (cg-RX-API-DMAC7.html)
HU (2) HUE028247T2 (cg-RX-API-DMAC7.html)
IL (3) IL170888A (cg-RX-API-DMAC7.html)
IS (2) IS2682B (cg-RX-API-DMAC7.html)
IT (1) ITMI20040682A1 (cg-RX-API-DMAC7.html)
LU (1) LU91867I2 (cg-RX-API-DMAC7.html)
MA (1) MA27729A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05010860A (cg-RX-API-DMAC7.html)
MY (1) MY141249A (cg-RX-API-DMAC7.html)
NO (4) NO329332B1 (cg-RX-API-DMAC7.html)
NZ (3) NZ542622A (cg-RX-API-DMAC7.html)
PE (5) PE20050396A1 (cg-RX-API-DMAC7.html)
PL (2) PL2316431T3 (cg-RX-API-DMAC7.html)
PT (1) PT1613288E (cg-RX-API-DMAC7.html)
RU (5) RU2358716C2 (cg-RX-API-DMAC7.html)
SG (1) SG175449A1 (cg-RX-API-DMAC7.html)
SI (2) SI2316431T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN05256A1 (cg-RX-API-DMAC7.html)
TW (1) TWI332847B (cg-RX-API-DMAC7.html)
WO (1) WO2004089341A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200507394B (cg-RX-API-DMAC7.html)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007001236A (es) * 2004-07-30 2007-03-23 Novartis Ag Formulaciones de compuestos de 2-amino-1, 3-propanodiol.
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
PT2295049E (pt) * 2005-09-09 2015-03-02 Novartis Ag Tratamento de doenças auto-imunes
WO2007056464A1 (en) 2005-11-09 2007-05-18 Proteolix, Inc. Compounds for enzyme inhibition
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
AU2007261345B2 (en) 2006-06-19 2012-02-23 Onyx Therapeutics, Inc. Peptide epoxyketones for proteasome inhibition
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
MX2009002993A (es) * 2006-09-26 2009-04-01 Novartis Ag Composiciones farmaceuticas que comprenden un modulador de s1p.
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
WO2008129846A1 (ja) 2007-03-29 2008-10-30 Daiichi Sankyo Company, Limited 医薬組成物
NZ598436A (en) 2007-10-04 2014-03-28 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
HUE027696T2 (en) 2007-10-12 2016-10-28 Novartis Ag Preparations containing sphingosine-1-phosphate (S1P) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
JP5452237B2 (ja) 2008-02-07 2014-03-26 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
RU2519660C2 (ru) 2008-03-17 2014-06-20 Актелион Фармасьютиклз Лтд Режим дозировки селективного агониста рецептора s1p1
BRPI0914164B1 (pt) * 2008-06-20 2019-04-30 Merck Patent Gmbh Comistura para produção de comprimidos de desintegração rápida em um processo de formação de comprimido direto, seus usos, e formulações de comprimido
EP2303250A1 (en) 2008-06-20 2011-04-06 Novartis AG Paediatric compositions for treating1 multiple sclerosis
SI2334202T1 (sl) * 2008-09-04 2012-04-30 Cargill Inc Tabletiranje eritritola
MX368109B (es) 2008-10-21 2019-09-18 Onyx Therapeutics Inc Terapia de combinacion con epoxicetonas peptidicas.
AU2013100531B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
CN102209705A (zh) * 2008-11-11 2011-10-05 诺瓦提斯公司 芬戈莫德盐酸盐的结晶形式
JP2012508215A (ja) 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
CN102256984B (zh) 2008-12-17 2014-09-03 第一三共株式会社 制备二胺衍生物的方法
WO2010082531A1 (ja) 2009-01-13 2010-07-22 第一三共株式会社 活性化血液凝固因子阻害剤
CN102348688B (zh) 2009-03-10 2014-07-09 第一三共株式会社 用于制备二胺衍生物的方法
CN102348680B (zh) 2009-03-13 2014-11-05 第一三共株式会社 用于制备光学活性二胺衍生物的方法
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
EP2444087B1 (en) * 2009-06-18 2016-09-07 Daiichi Sankyo Company, Limited Pharmaceutical composition having improved solubility
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
WO2011115067A1 (ja) 2010-03-19 2011-09-22 第一三共株式会社 抗凝固剤の溶出改善方法
WO2011115066A1 (ja) 2010-03-19 2011-09-22 第一三共株式会社 ジアミン誘導体の結晶およびその製造方法
EA201291095A1 (ru) * 2010-04-22 2013-04-30 Рациофарм Гмбх Способ получения пероральной лекарственной формы, содержащей финголимод
WO2012002538A1 (ja) 2010-07-02 2012-01-05 第一三共株式会社 光学活性ジアミン誘導体の塩の製造方法
US9266816B2 (en) 2010-11-25 2016-02-23 Shilpa Medicare Limited Fingolimod polymorphs and their processes
KR101951966B1 (ko) 2011-01-07 2019-02-25 노파르티스 아게 면역억제제 제제
WO2012100043A2 (en) 2011-01-19 2012-07-26 Pathlogica LLC Controlled release oral pharmaceutical dosage forms comprising mgbg
AR085749A1 (es) * 2011-04-01 2013-10-23 Novartis Ag Formulaciones
WO2013019872A1 (en) 2011-08-01 2013-02-07 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions comprising fingolimod
ES2673182T3 (es) 2011-08-10 2018-06-20 Daiichi Sankyo Company, Limited Composición farmacéutica que contiene un derivado de diamina
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
WO2014110154A1 (en) * 2013-01-08 2014-07-17 Pathologica Llc Methods and comp0stions for treatment of demyelinating diseases
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
WO2014175287A1 (ja) * 2013-04-26 2014-10-30 国立大学法人 京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
WO2013190151A1 (en) * 2013-05-13 2013-12-27 Synthon B.V. Pharmaceutical composition comprising fingolimod
MX2016001422A (es) * 2013-07-29 2016-10-05 Aizant Drug Res Solutions Pvt Ltd Composicion farmaceutica de fingolimod.
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2016026461A1 (en) * 2014-08-22 2016-02-25 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2016118515A1 (en) * 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
WO2022015348A1 (en) 2020-07-16 2022-01-20 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection
MX2023008907A (es) * 2021-01-28 2023-08-09 Priothera Sas Metodos de tratamiento con moduladores del receptor de esfingosina-1-fosfato (s1p).

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002792A1 (en) * 1997-04-04 2000-05-24 Yoshitomi Pharmaceutical Industries, Ltd. 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
WO2002018395A1 (en) * 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
DK0627406T3 (da) 1992-10-21 1999-07-12 Taito Co 2-Amino-1,3-propandiolforbindelser og immunundertrykkende midler
JP3870419B2 (ja) 1994-08-22 2007-01-17 三菱ウェルファーマ株式会社 ベンゼン化合物およびその医薬としての用途
PT812588E (pt) 1995-12-28 2005-01-31 Mitsubishi Pharma Corp Composicao farmaceutica externa para administracao topica contendo 2-amino-2-(2-(4-octilfenil)-etil)-propano-1,3-diol para o tratamento de doencas provocadas por uma afeccao imunitaria
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
CN1178653C (zh) * 1997-02-27 2004-12-08 三菱制药株式会社 药物组合物
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
KR20020027463A (ko) * 1999-07-12 2002-04-13 우에노 도시오 스핀고신-1-인산 수용체 아고니스트 또는스핀고신-1-인산을 유효 성분으로서 함유하는 선유화 억제제
CN1328387C (zh) 2000-07-13 2007-07-25 三共株式会社 氨基醇衍生物
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
IL157773A0 (en) 2001-03-26 2004-03-28 Novartis Ag 2-amino-propanol derivatives
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
WO2003020313A1 (en) 2001-09-04 2003-03-13 Ono Pharmaceutical Co., Ltd. Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
CA2460640C (en) * 2001-09-27 2011-03-29 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivatives, salts thereof and immunosuppressive agents using the same
WO2003029205A1 (fr) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Derive de sulfure de diaryle, son sel d'addition et immunosuppresseur
JP4709488B2 (ja) 2002-01-18 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
DE60329073D1 (de) 2002-01-18 2009-10-15 Merck & Co Inc Edg-rezeptoragonisten
AU2003216054B2 (en) 2002-01-18 2007-01-04 Merck & Co., Inc. Selective S1P1/Edg1 receptor agonists
CN101905023B (zh) * 2004-07-16 2012-07-11 杏林制药株式会社 有效的医药使用方法及与副作用发生的防御相关的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002792A1 (en) * 1997-04-04 2000-05-24 Yoshitomi Pharmaceutical Industries, Ltd. 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
WO2002018395A1 (en) * 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents

Also Published As

Publication number Publication date
PE20150676A1 (es) 2015-05-17
IS8114A (is) 2005-11-01
JP2004307506A (ja) 2004-11-04
AU2004228929A1 (en) 2004-10-21
US20080311188A1 (en) 2008-12-18
GB2400318A (en) 2004-10-13
NO335120B1 (no) 2014-09-22
NO334116B1 (no) 2013-12-16
RU2012148593A (ru) 2014-05-20
LU91867I9 (cg-RX-API-DMAC7.html) 2019-01-03
BRPI0409250B1 (pt) 2017-07-11
US20190175527A1 (en) 2019-06-13
GB2400318B (en) 2005-08-10
FR11C0036I2 (fr) 2023-12-29
AT504853A2 (de) 2008-08-15
PT1613288E (pt) 2009-02-25
AR078781A2 (es) 2011-11-30
FR11C0036I1 (fr) 2011-10-14
MA27729A1 (fr) 2006-01-02
US8324283B2 (en) 2012-12-04
US20220031609A1 (en) 2022-02-03
SG175449A1 (en) 2011-11-28
NO2011016I2 (no) 2012-08-27
PE20050396A1 (es) 2005-07-05
CY2011013I2 (el) 2014-04-09
ITMI20040682A1 (it) 2004-07-06
EP1613288B1 (en) 2008-11-19
NO20055231D0 (no) 2005-11-07
NO329332B1 (no) 2010-09-27
NO20100250L (no) 2006-01-09
NZ586280A (en) 2011-12-22
MXPA05010860A (es) 2006-05-25
ZA200507394B (en) 2007-03-28
HRP20100601A2 (hr) 2011-03-31
CN101797241B (zh) 2013-03-27
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29
TW200503784A (en) 2005-02-01
IL170888A (en) 2010-06-16
HRP20050886B1 (en) 2011-01-31
DK2316431T3 (en) 2016-01-11
HUE028247T2 (en) 2016-12-28
CN1767819B (zh) 2010-07-28
FR2854073A1 (fr) 2004-10-29
HRP20050886A2 (en) 2006-11-30
PE20131352A1 (es) 2013-11-14
RU2009105403A (ru) 2010-08-27
EP2319502A1 (en) 2011-05-11
CY1110260T1 (el) 2014-04-09
IS2682B (is) 2010-10-15
DE102004016947A1 (de) 2004-10-21
US20090203798A1 (en) 2009-08-13
US20130108675A1 (en) 2013-05-02
US20140011885A1 (en) 2014-01-09
ECSP056090A (es) 2006-03-01
US20110105620A1 (en) 2011-05-05
EP2008650A3 (en) 2011-04-27
KR20120101148A (ko) 2012-09-12
IS8885A (is) 2010-02-25
HUS1100016I1 (hu) 2016-08-29
HK1091114A1 (en) 2007-01-12
US20140255497A1 (en) 2014-09-11
IE20040246A1 (en) 2004-12-15
EP2316431B1 (en) 2015-09-30
AT501681A1 (de) 2006-10-15
PE20090743A1 (es) 2009-07-17
CN101797241A (zh) 2010-08-11
AT501681B1 (de) 2012-04-15
PE20130200A1 (es) 2013-03-09
NZ592339A (en) 2012-09-28
US20200237690A1 (en) 2020-07-30
TWI332847B (en) 2010-11-11
BE2011C030I2 (cg-RX-API-DMAC7.html) 2023-03-07
EP2008650A2 (en) 2008-12-31
KR101367574B1 (ko) 2014-02-25
SI1613288T1 (sl) 2009-04-30
PL1613288T3 (pl) 2009-07-31
AR078782A2 (es) 2011-11-30
SI2316431T1 (sl) 2016-04-29
US20170290787A1 (en) 2017-10-12
AR043987A1 (es) 2005-08-17
JP5495467B2 (ja) 2014-05-21
US20060275357A1 (en) 2006-12-07
CA2707750A1 (en) 2004-10-21
NO20131287L (no) 2006-01-09
KR20110005320A (ko) 2011-01-17
JP2011006461A (ja) 2011-01-13
HK1155647A1 (en) 2012-05-25
EP1613288A1 (en) 2006-01-11
ES2320767T3 (es) 2009-05-28
IL197578A0 (en) 2011-07-31
RU2475237C2 (ru) 2013-02-20
DE122011100047I1 (de) 2011-12-15
RU2010146697A (ru) 2012-05-27
FR2854073B1 (fr) 2008-03-14
ES2228282B1 (es) 2006-02-16
EP2769713A1 (en) 2014-08-27
CN1767819A (zh) 2006-05-03
ES2228282A1 (es) 2005-04-01
MY141249A (en) 2010-03-31
RU2005134173A (ru) 2006-09-10
NZ542622A (en) 2009-01-31
HRP20100600A2 (hr) 2011-03-31
IL242037A0 (en) 2015-11-30
GR20040100121A (el) 2004-12-17
TNSN05256A1 (en) 2007-07-10
CL2004000745A1 (es) 2005-02-11
LU91867I2 (fr) 2011-11-08
ES2556947T3 (es) 2016-01-21
DK1613288T3 (da) 2009-03-23
RU2475236C2 (ru) 2013-02-20
HRP20100601B1 (hr) 2016-12-02
IL197578A (en) 2015-10-29
RU2358716C2 (ru) 2009-06-20
GR1005052B (el) 2005-11-30
KR20050121712A (ko) 2005-12-27
JP2013177404A (ja) 2013-09-09
BRPI0409250B8 (pt) 2022-01-18
CA2521325A1 (en) 2004-10-21
CY1117071T1 (el) 2017-04-05
DE602004017847D1 (de) 2009-01-02
BRPI0409250A (pt) 2006-03-28
CY2011013I1 (el) 2014-04-09
RU2010147000A (ru) 2012-08-10
GB0407819D0 (en) 2004-05-12
WO2004089341A1 (en) 2004-10-21
DE202004021680U1 (de) 2010-04-22
ATE414508T1 (de) 2008-12-15
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
JP5543298B2 (ja) 2014-07-09
CA2521325C (en) 2010-09-14
NO2011016I1 (no) 2011-09-19

Similar Documents

Publication Publication Date Title
AU2004228929B2 (en) Organic compounds
AU2008200368B2 (en) Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
AU2011205050B2 (en) Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
HK1155650A (en) Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
HK1155647B (en) Solid oral composition comprising a s1p receptor agonist and a sugar alcohol
HK1091114B (en) Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
IE85095B1 (en) Pharmaceutical composition comprising a sphingosine-1 phosphate receptor agonist

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: GILENYA FINGOLIMOD

Filing date: 20110201

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: GILENYA FINGOLIMOD

Filing date: 20110201

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: GILENYA FINGOLIMOD

Filing date: 20110201

Extension date: 20260201

GD Licence registered

Name of requester: NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED